LEGN
Legend Biotech Corp
NASDAQ · Healthcare · Biotechnology · US
$22.77
+6.01%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$22.33
From 52W high−37.24%
Volume3.16M
Market cap$4.43B
P/E (TTM)—
P/S (TTM)3.5x
Div yield—
Key dataNov 4, 2026
Open
$22.33
From 52W high
−37.24%
Volume
3.16M
Market cap
$4.43B
ValuationView details →
P/E (Fwd)
39.0x
EV/EBITDA
1820.1x
P/E (TTM)
—
RSI (14)
62.4
MomentumView details →
1D Return
+6.01%
YTD Return
+1.31%
SummaryUpdated Jun 1, 2026
Legend Biotech Corporation (NASDAQ:LEGN) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Somerset, New Jersey. The company is a subsidiary of Genscript Biotech Corporation and went public in June 2020. Legend Biotech specializes in developing innovative cell therapies, particularly CAR-T (Chimeric Antigen Receptor T-cell) therapies for treating various cancers and other diseases. The company has achieved significant commercial success with its lead product CARVYKTI, which has become a leading treatment for multiple myeloma, and continues to expand its pipeline of cell therapy candidates targeting both blood cancers and solid tumors.
Similar companies
Latest newsMore news →
Legend Biotech Corp announced that it will present research on CARVYKTI and two CAR-T development programs at the 68th American Society of Hematology annual meeting in New Orleans from December 12 to 15.2h agoLegend Biotech Corp Sponsored ADR (LEGN) recently moved above its 200-day moving average.7d ago